877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Polycyclic organic compounds, matrixscientific.com, Antineoplastic drugs, Antineoplastic and immunomodulating drugs

Categories

Cyclic compounds (1)
Cycloalkanes (1)
Cyclopropanes (1)
Experimental cancer drugs (1)
Halides (1)
Organofluorides (1)
Organohalides (1)
Pharmaceuticals (1)
Piperazines (1)
Six-membered rings (1)
Tetracyclic compounds (1)
Three-membered rings (1)

Zosuquidar Trihydrochloride (167465-36-3)  
Zosuquidar (also LY-335979) is an experimental antineoplastic drug. In 2010, it was announced that a phase III trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome did not meet its primary endpoint and Eli Lilly discontinued its development. Zosquidir inhibits P-glycoproteins.

Related Results:
podophyllotoxin (4354-76-1, 477-47-4, 518-28-5)  
Podofilox  ·  Epipodophyllotoxin  ·  Condylox
Podophyllotoxin (PPT), also known as podofilox, is a medical cream that is used to treat genital warts and molluscum contagiosum. It is not recommended in HPV infections without external warts. It can be applied either by a healthcare provider or the person themselves.
thalidomide (50-35-1)  
Thalomid  ·  Celgene Brand of Thalidomide  ·  Sedoval
Thalidomide, sold under the brand name Immunoprin, among others, is an immunomodulatory drug and the prototype of the thalidomide class of drugs. Today, thalidomide is used mainly as a treatment of certain cancers (multiple myeloma) and of a complication of leprosy. Thalidomide was first marketed in 1957 in West Germany under the trade-name Contergan.
2,6-DIMETHYLQUINOLINE (877-43-0)  
2,6-dimethyl quinoline
4-Aminoquinoline (578-68-7)  
4-Aminoquinoline is a form of aminoquinoline with the amino group at the 4-position of the quinoline. A variety of derivatives of 4-aminoquinoline are antimalarial agents useful in treating erythrocytic plasmodial infections. Examples include amodiaquine, chloroquine, and hydroxychloroquine.
6-Methoxyquinoline (5263-87-6)  
6-methoxyquinoline hydrochloride
TASOSARTAN (145733-36-4)  
Tasosartan is an angiotensin II receptor antagonist. It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.
2-Methoxyphenothiazine (1771-18-2)  
R1663  ·  1-(2,2-difluoroethyl)pyrrolidine-3,4-dicarboxylic acid 3-((5-chloropyridin-2-yl)amide) 4-((2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl)amide)
Related searches
Polycyclic organic compounds
matrixscientific.com
Antineoplastic drugs
Antineoplastic and immunomodulating drugs
Next Page >